LivaNova PLC 2025 Annual Report (10-K) Summary
Business Context and Reporting Period
Company: LivaNova PLC (Nasdaq: LIVN)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: LivaNova is a global medical technology company operating in two reportable segments: Cardiopulmonary (heart-lung machines, oxygenators, cannulae) and Neuromodulation (VNS Therapy for epilepsy and depression, sleep apnea devices). The company wound down its Advanced Circulatory Support (ACS) segment in 2024, reallocating cannulae products to Cardiopulmonary.
Key Financial Metrics (Year Ended Dec 31, 2025)
| Metric | 2025 | 2024 | Change |
|---|---|---|---|
| Net Revenue | $1,388.1 million | $1,253.4 million | +10.7% |
| Gross Profit | $939.9 million | $853.5 million | +10.1% |
| Operating Income | $199.4 million | $129.1 million | +54.5% |
| Net Loss | $(242.5) million | $63.2 million (Income) | Turned to Loss |
| Operating Cash Flow | $254.3 million | $183.0 million | +39.0% |
| Total Debt | $376.7 million | $627.6 million | -40.0% |
| Cash & Equivalents | $635.6 million | $428.9 million | +48.2% |
Segment Performance:
- Cardiopulmonary Revenue: $785.4 million (+14.9% YoY), driven by consumables and Essenz Perfusion System sales.
- Neuromodulation Revenue: $592.8 million (+7.0% YoY), with growth across all regions.
Material Changes vs. Prior Period
The most significant material change in 2025 was a $365.6 million non-cash charge recorded for the SNIA environmental liability expense. This charge resulted from a March 2025 decision by the Italian Supreme Court holding LivaNova jointly and severally liable for environmental damages incurred by a former parent company (SNIA) prior to a 2004 demerger. This single item caused the company to report a net loss of $242.5 million, despite strong operating income of $199.4 million.
Excluding the SNIA charge, the company demonstrated improved operational efficiency:
- Operating Income increased 54.5% year-over-year.
- Cost of Sales as a percentage of revenue increased slightly to 32.3% (from 31.9%) due to product mix.
- SG&A decreased as a percentage of revenue to 39.5% (from 40.6%) due to fixed cost leverage.
- Debt Reduction: The company repaid $280.9 million in long-term debt during 2025, including an early repayment of $200 million on Term Facilities and the full maturity repayment of the 2025 Notes.
Guidance, Outlook, Risks, and Contingencies
Outlook & Management Commentary:
- SNIA Litigation: The case was referred back to the Court of Appeal to implement the Supreme Court's decision. The company has recorded a liability of $396.2 million (current) as its best estimate. Discussions for an out-of-court resolution are ongoing, but no assurance of settlement exists.
- Neuromodulation: The company initiated a process with CMS to seek reconsideration of national Medicare coverage for VNS Therapy in unipolar patients with treatment-resistant depression (TRD) following the RECOVER clinical study results.
- OSA: The OSPREY clinical trial for the aura6000 System met primary endpoints in 2024; a new advanced titration algorithm (PolySync) was announced in November 2025.
Key Risks & Contingencies:
- Environmental Liability: Beyond SNIA, the company faces potential costs related to the Saluggia site hazardous substances (estimated liability $41.8 million).
- Product Liability: Ongoing litigation regarding the 3T Heater-Cooler device. The provision for these matters was $15.6 million as of year-end.
- Cybersecurity: A November 2023 incident resulted in $13.1 million in direct costs. Insurance reimbursements of $10.7 million have been received, and the investigation by HHS was closed without penalties.
- Convertible Notes: The company has $345 million in 2.50% convertible senior notes due 2029. Conversion conditions were not met as of December 31, 2025.
Investor Verification Checklist
- SNIA Liability Finality: Verify the status of the Court of Appeal proceedings regarding the SNIA environmental liability and the potential for settlement versus the recorded $396.2 million provision.
- CMS Reimbursement: Monitor the outcome of the CMS reconsideration process for VNS Therapy in unipolar TRD patients, which is critical for Neuromodulation growth.
- Debt Structure: Confirm the terms and interest rate exposure of the remaining Term Facilities and the 2029 Convertible Notes, particularly regarding the embedded derivative valuation impacts on earnings.
- 3T Heater-Cooler Litigation: Track the number of filed claims and the adequacy of the $15.6 million litigation provision against potential future settlements.
- Restructuring Completion: Verify that the 2024 Restructuring Plan (winding down ACS) is fully complete with no residual unexpected costs.